The GIFT Nifty futures, which is an early indicator of the Nifty50 index, was trading 0.22% higher by 50 points at 22,678, indicating that the domestic benchmark indices are likely to make a positive start on Monday.
On Friday, 7 March, Domestic benchmark indices S&P BSE Sensex slipped by 8 points or 0.01% and settled at 74,333 while the Nifty50 traded 0.03% lower by 8 points, settling at 22,552.
Here are some stocks that are likely to remain in focus on 10 March.
Lupin: The company has announced the launch of Rivaroxaban tablets (USP, 2.5 mg) in the US after they received final approval from the US Food and Drug Administration (USFDA). Rivaroxaban tablets are used to reduce the risk of major cardiovascular events in patients with coronary artery disease.
RailTel Corporation: The company has announced securing a work order worth Rs 28.29 crore from the Northern railway that includes work for indoor and outdoor double-distant signaling. The company has also secured an order worth Rs 47.50 crore from East Central Railway.
Shilpa Medicare: The Unit-1 at Raichur of the company’s subsidiary, Shilpa Pharma Lifesciences was inspected by the USFDA between 3 March and 7 March. The US regulatory concluded the inspection by issuing Form 483 with one observation that is procedural in nature.
Tata Power: The subsidiary of the company, Tata Power Renewable Energy has announced signing a Memorandum of Understanding (MoU) with the Government of Andhra Pradesh for developing up to 7,000 megawatts (MW) for renewable energy projects that includes wind, solar, and hybrid projects.
HFCL: The company’s subsidiary, HTL, has announced that it is securing a contract worth Rs 44.36 crore to supply tactical optical fibre cable assemblies from the Indian Army.
India Pesticides: The company has announced signing a Power Purchase Agreement (PPA) and a Shareholders Agreement with Fourth Partner Solar Power, which is a special purpose vehicle (SPV) formed by Fourth Partner Energy. The scope of the agreement is to source solar power from the said SPV for a period of 25 years.
GR Infraprojects: The company’s Board of Directors have approved an interim dividend of Rs 12.50 per share for the current fiscal year, and the board has also approved divesting a 100% stake in GR Galgalia Bahadurganj Highway, which is a wholly-owned subsidiary of the company.
Container Corporation of India: The company has announced signing an MoU with The Energy and Resources Institute to set up a Centre of Excellence (COE) for green and sustainable logistics at TERI.
AstraZeneca Pharma India: The company has secured approval to import, sell, and distribute Durvalumab solutions from the Central Drugs Standard Control Organisation. Durvalumab is used to treat patients with limited-stage small-cell lung cancer.
The future of investing is here!
Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app todayand 10x your trading & investing journey!
